The NASH 700mg trial was totally pooched! I have little doubt it was due to Amarex but it could have been some other trial failure or sabotage. During the Pandemic, perhaps someone stole our LL and replaced it with saline solution.
Are we really to believe that LL worked at 350mgs but then, at 700mgs, the additional 350mgs went around and undid the benefit of the first 350mgs to bind with CCR5? This is stupid and not chemistry!
People have been wracking their brains to try to figure out the MOA that would have given these results. What crap! Leronlimab would have bound itself to CCR5 as it was intended to do and then the immune system would have taken it from there.
If NASH tests didn't demonstrate liver benefits, at least someone would have noticed their acne had gone away! Or some other health benefits. A tuned-up immune system will do that.
Chris Recknor, a couple times, made comments that seemed to indicate he thought he was working with valid trial date! That surprised me. But now it seems Cytodyn, at long last, realizes the data fed to them was utterly bogus! There is no unknown MOA to be found that can explain those results!
I said most of this in this msg four and a half months ago -
https://investorshangout.com/post/view?id=6425953
What I didn't say was how stupid it was to think that more LL undid the benefit realized by the weaker dose all the way back to placebo level! What bullshit! This was a total non sequeteur. It just didn't compute.
I hope that, on this board, we never hear again any more nonsense about how we should figure out the MOA for those totally out of character trial results. The trial simply has to be done over again for 700mgs. I have little doubt it will improve on the 350mgs results!
Are we really to believe that LL worked at 350mgs but then, at 700mgs, the additional 350mgs went around and undid the benefit of the first 350mgs to bind with CCR5? This is stupid and not chemistry!
People have been wracking their brains to try to figure out the MOA that would have given these results. What crap! Leronlimab would have bound itself to CCR5 as it was intended to do and then the immune system would have taken it from there.
If NASH tests didn't demonstrate liver benefits, at least someone would have noticed their acne had gone away! Or some other health benefits. A tuned-up immune system will do that.
Chris Recknor, a couple times, made comments that seemed to indicate he thought he was working with valid trial date! That surprised me. But now it seems Cytodyn, at long last, realizes the data fed to them was utterly bogus! There is no unknown MOA to be found that can explain those results!
I said most of this in this msg four and a half months ago -
https://investorshangout.com/post/view?id=6425953
What I didn't say was how stupid it was to think that more LL undid the benefit realized by the weaker dose all the way back to placebo level! What bullshit! This was a total non sequeteur. It just didn't compute.
I hope that, on this board, we never hear again any more nonsense about how we should figure out the MOA for those totally out of character trial results. The trial simply has to be done over again for 700mgs. I have little doubt it will improve on the 350mgs results!
12
